No green light for libido-boosting drug for women: US FDA
Friday 18 June 2010
The pink pill German drug firm Boehringer Ingelheim is trying to market in the United States as a libido-booster for women produced inconclusive results in two clinical trials, the Food and Drug Administration (FDA) said Wednesday.
Originally intended as an anti-depressant, the drug flibanserin - in the form of a pink pill - began being tested years ago as a potential libido aid after women said it failed to fight the blues but did boost their sex drive.
Lack of desire is the most common sexual problem in women aged 30 to 60, just as erectile dysfunction is the most common sexual disorder among men in the same age bracket, researchers said.
Clinical trials to test flibanserin's efficacy in raising the level of sexual desire in women were held in Canada, Europe and the United States.
The results of two US trials with the drug and a placebo were published on the FDA's website: "both failed to demonstrate a statistically significant improvement on the co-primary endpoint of sexual desire," said the FDA.
"Therefore, neither study met the agreed-upon criteria for success in establishing the efficacy of flibanserin for the treatment of HSDD (hypoactive sexual desire disorder)," the administration added.
Besides the inconclusive results, the FDA noted the drug in some patients caused side effects including depression and dizzyness.
The FDA said its is waiting for recommendations on the little pink pill from an independent panel of experts due to report on Friday. The administration is not legally bound to comply with the advice, but usually does.
Boehringer Ingelhein has been researching flibanserin as a treatment for post-menopausal HSDD in women since the popular Viagra hit the market for male ED in 1998.
The potential market for a libido booster for women has been estimated by some analysts at around two billion dollars.
Medical research has found that 40 percent of women suffer from different degrees of HSDD.
Flibanserin belongs to a family of anti-depressants that acts on the body's level of serotonin, a molecule that plays a role in mood changes.
Life & Style blogs
Snapchat removed the Best Friends list feature and 'stalkers' are upset
Virtual reality thrusts viewers into the frontline of global events - and puts film-goers at the heart of the action
Fifty years of David Bowie's hairstyles in one animated gif
A bottle of wine a day is not bad for you and abstaining is worse than drinking, scientist claims
Eight-year-old girl Camilla Lisant suggests possible cure for cancer to her scientist father
- 4 Amal Clooney gives excellent response to fashion question at European Court of Human Rights
- 5 A bottle of wine a day is not bad for you and abstaining is worse than drinking, scientist claims
£29000 per annum: Ashdown Group: Application Support Analyst- (Customer Suppor...
£14500 - £15000 per annum: Recruitment Genius: This is an exciting opportunity...
£22000 - £28000 per annum: Recruitment Genius: A PPC Executive/Manager is requ...
£55000 per annum: Ashdown Group: Service Delivery Manager - Retail / FMCG / WM...